198 related articles for article (PubMed ID: 16297482)
1. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
Singer JW
J Control Release; 2005 Dec; 109(1-3):120-6. PubMed ID: 16297482
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer.
Bonomi P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):415-22. PubMed ID: 17428162
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.
Singer JW; Shaffer S; Baker B; Bernareggi A; Stromatt S; Nienstedt D; Besman M
Anticancer Drugs; 2005 Mar; 16(3):243-54. PubMed ID: 15711176
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Boddy AV; Plummer ER; Todd R; Sludden J; Griffin M; Robson L; Cassidy J; Bissett D; Bernareggi A; Verrill MW; Calvert AH
Clin Cancer Res; 2005 Nov; 11(21):7834-40. PubMed ID: 16278406
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases.
Shaffer SA; Baker-Lee C; Kennedy J; Lai MS; de Vries P; Buhler K; Singer JW
Cancer Chemother Pharmacol; 2007 Mar; 59(4):537-48. PubMed ID: 16924498
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.
Paz-Ares L; Ross H; O'Brien M; Riviere A; Gatzemeier U; Von Pawel J; Kaukel E; Freitag L; Digel W; Bischoff H; García-Campelo R; Iannotti N; Reiterer P; Bover I; Prendiville J; Eisenfeld AJ; Oldham FB; Bandstra B; Singer JW; Bonomi P
Br J Cancer; 2008 May; 98(10):1608-13. PubMed ID: 18475293
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel poliglumex for ovarian cancer.
Galic VL; Wright JD; Lewin SN; Herzog TJ
Expert Opin Investig Drugs; 2011 Jun; 20(6):813-21. PubMed ID: 21470062
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study.
Dipetrillo T; Milas L; Evans D; Akerman P; Ng T; Miner T; Cruff D; Chauhan B; Iannitti D; Harrington D; Safran H
Am J Clin Oncol; 2006 Aug; 29(4):376-9. PubMed ID: 16891865
[TBL] [Abstract][Full Text] [Related]
10. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.
Chipman SD; Oldham FB; Pezzoni G; Singer JW
Int J Nanomedicine; 2006; 1(4):375-83. PubMed ID: 17722272
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
[TBL] [Abstract][Full Text] [Related]
12. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy.
Li C; Ke S; Wu QP; Tansey W; Hunter N; Buchmiller LM; Milas L; Charnsangavej C; Wallace S
Clin Cancer Res; 2000 Jul; 6(7):2829-34. PubMed ID: 10914731
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.
Li C; Newman RA; Wu QP; Ke S; Chen W; Hutto T; Kan Z; Brannan MD; Charnsangavej C; Wallace S
Cancer Chemother Pharmacol; 2000; 46(5):416-22. PubMed ID: 11127947
[TBL] [Abstract][Full Text] [Related]
14. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
Li C; Yu DF; Newman RA; Cabral F; Stephens LC; Hunter N; Milas L; Wallace S
Cancer Res; 1998 Jun; 58(11):2404-9. PubMed ID: 9622081
[TBL] [Abstract][Full Text] [Related]
15. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
O'Brien ME; Socinski MA; Popovich AY; Bondarenko IN; Tomova A; Bilynsky BT; Hotko YS; Ganul VL; Kostinsky IY; Eisenfeld AJ; Sandalic L; Oldham FB; Bandstra B; Sandler AB; Singer JW
J Thorac Oncol; 2008 Jul; 3(7):728-34. PubMed ID: 18594318
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors.
Veronese ML; Flaherty K; Kramer A; Konkle BA; Morgan M; Stevenson JP; O'Dwyer PJ
Cancer Chemother Pharmacol; 2005 May; 55(5):497-501. PubMed ID: 15711828
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical.
Man M; Rugo H
IDrugs; 2005 Sep; 8(9):739-54. PubMed ID: 16118697
[TBL] [Abstract][Full Text] [Related]
19. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data.
Singer JW; Baker B; De Vries P; Kumar A; Shaffer S; Vawter E; Bolton M; Garzone P
Adv Exp Med Biol; 2003; 519():81-99. PubMed ID: 12675210
[No Abstract] [Full Text] [Related]
20. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes.
Langer CJ
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S85-8. PubMed ID: 15638965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
